Multiple site place-of-care manufactured anti-CD19 CAR-T cells induce high remission rates in B-cell malignancy patients
- Resource Type
- article
- Source
- Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
- Subject
Science - Language
- English
- ISSN
- 2041-1723